Dementia is a major public health issue with rising prevalence rates, but many individuals remain undiagnosed. Accurate and timely diagnosis is key for the optimal targeting of interventions. A noninvasive, easily measurable peripheral biomarker would have greatest utility in populationwide diagnostic screening. Epigenetics, including DNA methylation, is implicated in dementia; however, it is unclear whether epigenetic changes can be detected in peripheral tissue. This study aimed to systematically review the evidence for an association between dementia and peripheral DNA methylation. Forty-eight studies that measured DNA methylation in peripheral blood were identified, and 67% reported significant associations with dementia. However, most studies were underpowered and limited by their case-control design. We emphasize the need for future longitudinal studies on large well-characterized populations, measuring epigenetic patterns in asymptomatic individuals. A biomarker detectable in the preclinical stages of the disease would have the greatest utility in future intervention and treatment trials.
Introduction
Dementia is a substantial public health issue with huge social and economic burden. Approximately 47 million people worldwide were living with dementia in 2015, and this is estimated to rise to 131 million within the next 35 years [1] . The most common cause of dementia is Alzheimer's disease (AD), a progressive and highly debilitating neurodegenerative disorder accounting for two-thirds of dementia cases [2] . AD is characterized by the buildup of extracellular amyloid b (Ab) senile plaques and intracellular neurofibrillary tangles-aggregates of hyperphosphorylated tau protein. A definitive diagnosis of AD can only be made using neuropathological techniques postmortem [3] .
Accurate and timely diagnosis of probable AD in living individuals is challenging. The most commonly used criteria recommend detailed clinical examinations and neuropsychological testing, a comprehensive medical history, laboratory tests on cerebrospinal fluid (CSF) and/or blood [4] , and imaging (i.e., magnetic resonance imaging [MRI] , positron emission tomography [PET] , and/or computerized tomography [CT]) [5, 6] . However, these are time consuming and expensive, with a heavy burden on the individual, and require a specialist's knowledge for their interpretation. Indeed, many cases of dementia remain undiagnosedalmost half of all individuals in high-income countries and up to 90% of those living in low-and middle-income areas [1] . Furthermore, it is now clear that there is a long preclinical phase of AD and identifying individuals in this asymptomatic phase would not only permit earlier interventions but may also be crucial to the success of existing and future therapeutic treatments [7] .
A major area of current research has thus been the search for robust and readily accessible biomarkers of AD. To date, most attention has focused on brain imaging and CSF biomarkers that target key neuropathological features of the disease, such as brain Ab and neurodegeneration. Promising biomarkers for AD include heightened brain Ab detected with PET and cerebral atrophy observed with MRI. A decline in Ab and increase in CSF tau have also been observed [8] . Importantly, these biomarkers have been observed in individuals before the emergence of clinical symptoms. However, despite their relative predictive accuracy, none are yet considered as diagnostic biomarkers for routine use in clinical practice [9] . One of the reasons is the lack of specificity of these biomarkers for distinguishing preclinical dementia from cognitive decline that is considered a normal part of aging [10, 11] . Individuals positive for these biomarkers also display varying trajectories of disease progression that appear to be influenced by genetic and lifestyle factors [10] . Other major limitations with these biomarkers are their cost, invasiveness, and burden for individuals, thus limiting their usefulness for population-wide screening.
Further research has thus focused on identifying a robust biomarker of dementia, which can be measured in peripheral tissue and could be incorporated into routine screening, being noninvasive, widely accepted by individuals and relatively inexpensive to measure. Epigenetic biomarkers represent a potential candidate, and research in this area has expanded greatly over the last decade.
Epigenetics describes dynamic molecular modifications "above the level of the DNA," which do not alter the genetic code but influence the way the genes encoded by the DNA are expressed. These molecular modifications, some of which are sensitive to underlying genetic variation, are often sensitive to environmental factors or are influenced by disease state [12] . Despite the tissue specificity of epigenetics, peripheral blood-based epigenetic biomarkers have shown promise in several fields of medical research and diagnostics. Some of the strongest and most consistent results include the finding that smoking alters DNA methylation of specific genes and can be detected in peripheral blood [13] . DNA methylation signatures derived from peripheral blood have also been used to predict mortality [14, 15] . Other more preliminary findings include hypomethylation of a particular gene in blood as a precancer biomarker [16] , and depression may be associated with specific DNA methylation changes in peripheral tissue [17] , despite it being a brain disorder. This growing trend has also given rise to studies that have investigated the potential for peripheral epigenetic biomarkers of AD. Given the exponential rise in research in this field over the last decade, it is timely to conduct a systematic review of the current state of this research.
The aim of our study was to determine the potential for a peripheral epigenetic biomarker of dementia, by conducting a systematic review of studies undertaken in this area to date.
Methods
The protocol for this systematic review was registered with the International Prospective Register of Ongoing Systematic Reviews (PROSPERO) [18] , registration number: CRD42017067306 [19] . This systematic review was conducted following PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analyses) [20] with the relevant checklist included in Supplementary Table 3 . For brevity, the detailed description of the full methods used, including the selection criteria, search strategy, manuscript selection, data extraction, and the critical assessment of each manuscript, are shown in Supplementary Materials 1 and Supplementary Tables 1 and 2 . In short, we included any human studies published in English up until April 2017, which measured peripheral epigenetic biomarkers and compared these between individuals with and without dementia.
Results

Search results
A total of 375 studies were identified through the original search after removing duplicates ( Fig. 1 ) [20] , and a further 184 studies were excluded as they were found not to be relevant. This left 191 eligible articles for full-text assessment. At this stage, we further excluded reviews, editorials, conference abstracts, and animal and in vitro studies. We also excluded studies that did not assess dementia or measure DNA methylation. All remaining articles (n 5 48) fulfilled the following inclusion criteria: (1) DNA methylation was measured in peripheral blood and (2) compared between individuals with dementia and another group . Included studies were published between 2008 and 2017. A summary of the extracted data is shown in Table 1 .
Characteristics of included studies
Study design
Of the 48 studies, 44 were case-control studies (ranging between 2 and 356 participants), which included two studies that used biobanked samples in a case-control design [29, 41] . One case-control study of 1177 participants involved only a subsample of participants in their analysis, but the exact number was unclear [61] . Two of the studies were cohorts (with 52 and 71 participants, respectively) [33, 57] , and there were two small case reports (n 5 6 and 3, respectively) [66, 68] .
Participants
Participants in most of the studies (92.6%) were in lateadulthood or older age, with the average age ranging between 57.8 and 83.8 years. Four studies also included controls from a younger healthy population (average age ranged between 21.1 and 21.7 years) [50, 51, 55, 56] . One case report study included a 27-year-old individual, and two siblings of undisclosed age [68] . The age of cases and controls was not clearly stated in 10 other studies [29, 33, 47, 59, 61, 62, 64, [66] [67] [68] .
Most studies included males and females (ranging from 9% to 78% females), however, there were two studies of females only [22, 45] and one study of males only [34] . Nine studies did not state the sex of study participants [29, 38, 44, 55, 61, 62, [66] [67] [68] .
Populations were diverse in ethnicity and described as Italians [21, 27, 35, 37, 48, 49, 60, 65] , Japanese [24, 31, 32, 42, 58] , European [33, 42] , Chinese [45, 68] , Han Chinese [23, 38] , and Caucasian [66] . Another four studies included individuals of mixed ethnicity [42, 59, 65, 67] . However, in 27 studies (56%), ethnicity was not mentioned.
One study [61] provided no information about the numbers of participants or their characteristics.
Dementia assessment
Most studies (75%) focused on AD, nine of thirty-six studies that specifically mentioned late-onset AD, although in all studies individuals with AD were aged over 65 years. These studies all compared individuals with AD to older individuals without a diagnosis, and as previously mentioned, four studies also included a younger healthy control group. One study investigated all-cause dementia in older individuals [57] who were followed over time, and another study included a group of participants with vascular dementia (VD) [25] . Five case-control studies [26, 59, 61, 62, 64] and one case report [68] involved individuals with frontotemporal dementia (FTD), three of which also included a group with amyotrophic lateral sclerosis (ALS) [61, 62, 64] . Two separate studies investigated dementia with Lewy bodies (DLB) [54, 58] .
Most studies (54.2% of all included studies and 72.2% of AD-related studies) used National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for the diagnosis of probable dementia or AD. This was commonly in association with the Diagnostic and Statistical Manual of Mental Disorders (III or IV revision) (22.9% of studies). The most frequently used tools to support this diagnosis included the Mini-Mental AD hypermethylation of SIRT1 (SI) (no effect size or P value given), increase at 7 of 11 sites and decrease in APP (P , .05, no effect size given) [29, 40, 59] . A number of studies investigated individuals with rare genetic diseases (where dementia was a principal symptom) and compared these individuals to family members without the gene mutation. There was a case study that observed an individual with a MAPT mutation [68] . Mutations in MAPT, which encodes microtubule-associated protein tau and is an integral part of the development of the nervous system, are a major cause of FTD. Two studies were focused on hereditary sensory and autonomic neuropathy type 1 with dementia and hearing loss (HSAN1) [66, 67] , whereas five studies investigated a gene mutation in the chromosome 9 open reading frame 72, of which G 4 C 2 repeats are thought to be the most common genetic cause of ALS and FTLD [61] [62] [63] [64] [65] . In all cases, these diagnoses were based on medical records.
DNA methylation measure
The vast majority of studies were cross-sectional, and blood was collected at the same time when dementia was assessed. One prospective study [57] measured DNA methylation at follow-up and determined the association with a prior dementia diagnosis. Only one study collected blood samples at baseline, before dementia diagnosis [33] .
All studies extracted DNA from peripheral blood, the majority using whole blood (28 studies, 58.3%), of which only two were not cross-sectional. Some studies reported the use of white blood cells, described specifically as leukocytes in eight studies [25, 34, 45, 46, 50, 51, 58, 68] ; mononuclear cells in six studies [22, 26, 35, 36, 44, 52] ; lymphocytes in two studies [43, 47] ; and CD41 T cells [33] , B cells [66] , and monocytes [40] in one study each.
The methods for measuring DNA methylation varied widely with 24 different methods described. The most common was pyrosequencing, which was used in 13 studies [23, 24, 26, 28, 31, 32, 35, 38, 47, 53, 58, 67, 68] , which is a direct-sequencing technique enabling single-nucleotide resolution for short DNA stretches. The other common technique for targeted gene analysis is matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MassARRAY; Sequenom EpiTYPER) and was used in three studies [42, 50, 51] .
Only one study used whole-genome sequencing with HiSeq 2000 [66] . Nine studies used chip array technology that enabled simultaneous measures of thousands of loci in a hypothesis-free approach, to investigate methylation patterns throughout the genome. Six studies used the Illumina Infinium HumanMethylation450 BeadChip (HM450K) [28, 29, 33, 41, 57, 59] , and two studies used the smaller Infinium HumanMethylation27 BeadChip (HM27K) [30, 67] , which measure methylation at .450,000 and .27,000 5'-Cytosine-phosphate-Guanine-3' (CpG) sites, respectively. Finally, one study used a much smaller array containing 22 genes, the DNA Repair EpiTect Methyl II PCR Array [21] .
Critical appraisal
We performed a critical appraisal of all the studies using established and widely employed criteria-the Joanna Briggs Institute Critical Appraisal tools [79] . This enabled an unbiased systematic evaluation of the quality of evidence from each study. Full details are provided in Supplementary  Table 2 .
The two cohort studies [33, 57] and the two case reports [66, 68] all scored quite highly (71.4%, 92.9% and 80%, 90%, respectively), when critically evaluated against the defined criteria [79] . The majority of studies were casecontrol, scored from 16.7% [64] to 94.4% [25, 37] in their critical appraisal, with the mean being 54.2%. Most used validated tools to measure DNA methylation (93%, Q8 on the criteria checklist) and assess dementia (86%, Q4), and 88.4% of studies used appropriate statistical analysis as far as could be assessed (Q10). However, many studies (n 5 32) did not use the same criteria for the identification of dementia cases and controls (Q3), or detailed information on this was not provided (thus classified as "unclear" in this evaluation). Furthermore, confounding factors were not considered in 55.8% of studies (Q6), 16 .3% did not provide sufficient detail to ascertain whether they had investigated confounding (Q7), and 69.8% did not adjust for any factors.
Summary of outcomes
Although 32 studies reported differences in methylation between individuals with dementia and those without, the high heterogeneity across studies, particularly in regard to the method of methylation measurement and genes investigated, prohibited any meta-analysis of the results. Instead, we report below a summary of the main findings.
Methylation differences between AD cases and controls
Overall, 36 studies compared methylation between individuals with AD and those without, with all but one [33] casecontrol study. In addition, a cohort study investigated all-cause dementia in older adults [57] , with AD a likely cause in the majority of cases. Overall, 66.6% of AD studies reported methylation differences between the groups, but the genes investigated and those found to be associated varied widely.
Epigenome-wide association studies of AD
Of the seven studies using the HM450K for epigenomewide methylation analysis, four focused on AD and one all-cause dementia ( Table 2) . One study (n 5 15) found some small differences between groups (,5%) [33] , and another (n 5 57) reported 805 differentially methylated sites [29] . Both studies, however, failed to provide detailed information on the exact loci identified and/or the effects sizes and statistical significance. Loci in three genes (DAPK1, GAS1, and NDUFS5) were also reported to be differentially methylated in AD cases compared with controls (n 5 57); however, no effect size or statistics were given [41] . Another study (n 5 12) found 1021 differentially methylated loci, which differed in methylation between AD cases, individuals with mild cognitive impairment (MCI), and controls, and 156 of these were also associated with cognitive symptoms [28] . More specifically, this study found 4193 differentially methylated sites between controls and AD, but no further details were provided. The one cohort study (n 5 52), investigating all-cause dementia also used the HM450K array and found an association between dementia and DNA methylation age (b 5 0.16, P 5 .019), which is assessed using a combination of sites on the array [57] .
Only one of the two studies that used the smaller HM27K array (methylation analysis at 27,000 sites, rather than 450,000) investigated AD (n 5 128). They found lower average HMOX1 methylation in association with AD compared with both MCI and control groups (77.94% 6 13.0 vs. MCI: 89.15 % 6 5.9 and controls: 87.20% 6 3.1, no P value stated).
Global methylation studies
Four studies, including two on AD, only examined global methylation. AD was found to be associated with increased global methylation (n 5 81, 67.10 6 0.7 vs. 64.73 6 0.6, P 5 .0122), measured using luminescent methylation analysis [35] . The other study (n 5 194) used an Imprint methylated DNA quantification kit MDQ1 and found no difference in methylation between AD cases and controls, but individuals with VD had increased methylation [25] .
Common gene regions within AD studies
Genes that were commonly investigated in more than one study are listed in Table 3 . The most consistently significant finding was an increase in BDNF methylation in individuals with AD compared to controls, in two studies of Asian populations (n 5 40, 5.08 6 5.52% vs. 2.09 6 0.81%, P 5 .041 [36] ; n 5 106, 9.50 6 4.43% vs. 7.45 6 2.77%, P 5 .004 [38] ). This, however, was not shown in a study of 40 Caucasians [34] . Two studies of PIN1, and using the same method to assess methylation, found a decrease in methylation in association with AD (n 5 60, 3.76 6 0.89% vs. 11.45 6 2.26%, P 5 .001 [48] ; n 5 2, 0.9% vs. 2.9% [22] ). However, a third much larger study (n 5 317) failed to find any differences [26] .
Another consistency was seen in the reporting of null findings for a number of genes. All three studies of apolipoprotein E (APOE) (n 5 2, 135, and 15, respectively) [22, 46, 47] and MTHFR (n 5 14, 200, and 135, respectively) [21, 27, 37] and two studies each of DNMT1 [27, 37] and DNMT3B [27, 37] (n 5 200 and 135 respectively) reported no significant association between AD and methylation. A couple of other genes, PSEN1 and SIRT1, were investigated in more than two studies. While the majority of studies reported no significant association, one study reported decreased PSEN1 methylation and another SIRT1 hypermethylation in association with AD, although no effect size or P value was given [27, 46] .
Other dementia-associated disease methylation studies
Further summaries on studies including FTD/FTLD, DLB, and genetic mutations leading to dementia may be found in Supplementary Materials 2.
Discussion
Overall 67% of all studies (32 of 48) reported a statistically significant difference in peripheral blood DNA methylation between individuals with dementia and those without, which included 67% of studies that examined AD (24 of 36). However, of these AD studies, very few investigated DNA methylation in the same gene, and none of the loci identified Abbreviations: AD, Alzheimer's disease; aMCI, amnestic mild cognitive impairment; DNAm, DNA methylation; HM450K, Infinium HumanMethylation450 BeadChip; HM27K, Infinium HumanMethylation27 BeadChip; PB CD41 Tc, Peripheral blood CD41 T cells; WBC, white blood cells; WPB, whole peripheral blood.
from epigenome-wide association were replicated across studies. The vast majority of findings came from small cross-sectional case-control studies in varying populations, and this may help account for the divergent findings. It remains uncertain whether peripheral DNA methylation marks differ between individuals with other causes of dementia, including FTD, DLB, and genetic mutations that result in dementia symptoms, due to the small number of studies undertaken to date.
Strength of evidence
This review was based on 48 studies including a total of 5689 participants. The average sample size of studies was relatively small, limiting analytical power. The 36 studies of AD had a total number of participants ranging between 2 and 283 (combined cases and controls), with a mean of 91. The median number of participants in studies of FTD was 102, and the five studies of C9orf72 ranged in total number between 38 and 1177 individuals (including affected individuals, family members, and unrelated controls). The relatively small size of most of these studies precluded testing for sexspecific effects in stratified analyses, despite clear evidence of this in the broader field of epigenetics [80, 81] .
Overall, a small number of cohort studies and case reports were found to be quite robust and presented good-quality evidence. The majority of studies included in this review, however, were case control, and they were found to be variable in their quality. A key feature of case-control studies is that the individuals should be as similar as possible and recruited from the same overall population, differing only in their diagnosis of dementia. However, a large number of studies (46.5%) did not fulfill these criteria, and for others, it was unclear (27.9%). This is likely to result in selection bias, which may influence the results. Another area where several studies performed poorly was a failure to adequately consider potential confounding factors, as they were not sufficiently investigated or controlled for in .69% of studies. Given that Table 3 Candidate genes examined in more than one AD study Study Gene (n) Methylation method DNA methylation association
[22] APOE 2 MSP rtPCR None [46] 135 mPCR None [47] 15 Pyrosequencing None [22] APP 2 MSP rtPCR Increase (4.1% vs. 3.6%), no P value given [46] 135 MSP Decrease, no effect given (P , .05) [27] BACE1 200 MS-HRM Nonsignificant increase (0.5 6 0.9 vs. 0.8 6 1.2, P 5 .06) [37] 135 MS-HRM Nonsignificant increase (0.62 6 0.11 vs. 0.74 6 0.11, P 5 .12) [34] BDNF 40 MSP rtPCR None [38] 106 Pyrosequencing Increased mean (9.50 6 4.43 vs. 7.45 6 2.77, P 5 .004) and at all CpGs [36] 40 ABI 3730 DNA analyzer Increase (5.08 6 5.52% vs. 2.09 6 0.81%, P 5 .041) and at 1 site (4.85 6 6.91 vs. 0 6 0, P 5 .014) [27] DNMT1 200 MS-HRM None [37] 135 MS-HRM None [27] DNMT3A 200 MS-HRM None [37] 135 MS-HRM Nonsignificant decrease (0.90 6 0.25 vs. 1.59 6 0.26, P 5 .10). [27] DNMT3B 200 MS-HRM None [37] 135 MS-HRM None [53] LINE-1 81 Pyrosequencing Increase (83.6% vs. 83.1%, P 5 .02). [39] 58 MS-HRM None [21] MTHFR 14 22 gene array None [27] 200 MS-HRM None [37] 135 MS-HRM None [48] PIN1 60 MSP rtPCR Decrease (3.76 6 0.89 vs. 11.45 6 2.26, P 5 .001). [22] 2 MSP rtPCR Decrease (0.9% vs. 2.9%), no P value given [26] 317 Pyrosequencing AD, none. FTD increase compared to AD and controls (D,0.4%, P , .03) [34] PSEN1 40 MSP rtPCR None [21] 14 22 gene array None [22] 2 MSP rtPCR None [27] 200 MS-HRM Nonsignificant decrease (0.6 6 1.2 vs. 0.9 6 1.9, P 5 .18). [37] 135 MS-HRM None [34] SIRT1 40 MSP rtPCR None [22] 2 MSP rtPCR None [50] 84 Sequenom EpiTYPER None [46] 135 MSP Hypermethylation (no effect size/P value given) [45] Sub-telomeric DNA 52 MspI and HpaII telomere length distributions None [52] 99 Faster telomeric hypomethylation with aging (D 0.0435 vs. D 0.0340, no P value given).
Abbreviations: APOE, apolipoprotein E; FTD, frontotemporal dementia; MSP rtPCR, methylation-specific primer real time PCR; mPCR, methylationspecific PCR; MS-HRM, methylation-sensitive high-resolution melting analysis.
DNA methylation is sensitive to many environmental influences and that individuals with dementia are likely to differ on a number of key characteristics (including medication history) compared to individuals without dementia, confounding by other factors may account (at least in part) for some of the findings.
Completeness and applicability of the evidence
Although 48 individually published studies were included in this review, a number of these came from the same research group, and often using very similar populations. This limits the overall generalizability of the results. For example, a total of seven AD case-control studies involved individuals recruited in Milan, Italy [26, 35, 44, 48, 49, 53, 60] , and a further three studies also involved an Italian population [21, 27, 37] . Together these studies represent over 30% of all included studies of peripheral methylation and AD. There were also five studies involving Japanese individuals, three of which had very similar population characteristics and recruitment [24, 31, 32] , and six studies of Chinese, two involving the same case-control cohort investigating different genes [50, 51] and others with similar populations ( [23, 38] and [45, 52] ). Together this suggests that a large proportion of the findings in this review are based on the same or very similar groups of individuals.
Furthermore, ethnicity was not reported in over half (56%) of the studies presented. This, together with the failure to consider underlying genetic variation in all DNA methylation studies of AD included here, is also an important limitation given the known role of genetic variation in determining DNA methylation patterns. It is widely accepted that differential methylation can be associated with genetic variations, such as single-nucleotide polymorphisms [82] or variable number tandem repeats [83] . In this review, differential methylation was associated with the genetic repeats of C9orf72 expansions [61, 64] . However, there is a lack of studies that have combined genetic information and methylation marks when comparing individuals with dementia and those without.
Strengths and limitations of this review
This review offers a comprehensive summary of studies investigating peripheral blood DNA methylation in dementia. A strength of the search strategy was the inclusion of all possible causes of dementia, including rare genetic conditions that result in symptoms of dementia. We comprehensively extracted all relevant information from 48 identified studies and completed a quality assessment using recognized evaluation tools. Some limitations of the review are the inclusion of only studies published in English and which were identified from the two most comprehensive databases of published medical literature. Some published studies, however, may not have been included. We also need to consider positive publication bias, and those studies with negative results may not have been published and thus could not be included here. Finally, we decided to focus on DNA methylation, given the large scope of studies already published in this field, but cannot draw any conclusions regarding other possible epigenetic biomarkers of dementia.
Broader limitations of research in this field
Beyond the limitations of this review, per se, are a number of other important considerations to current research in this area more generally.
Complexity of dementia diagnosis
Dementia is an umbrella term used to describe a group of symptoms that result in long-term decline in cognitive functioning that is significant enough to affect daily function [84] . Diagnosis of dementia is complicated, and the underlying cause (e.g., AD, VD, or DLB) is not always clear. Yet these diseases are likely to have different etiologies and the associated epigenetic patterns may therefore also be quite different. Many studies in this review focused on AD; however, a definitive diagnosis can only be made postmortem. Studies have thus classified with possible/probable AD, often using NINCDS-ADRDA criteria, but without providing specific details on the neuropsychological tests, clinical exams, imaging, or blood tests, which were used. Misclassification of the underlying cause of dementia would have influenced some of the findings. However, this is a challenge that cannot be easily overcome and also one of the reasons driving the need for more research in this area.
Study design
To date, almost all studies have been case-control studies, where a group of individuals with dementia is recruited (together with a control sample) and DNA methylation measured at that same point in time. Such cross-sectional analysis is limited because of the lack of temporal information. DNA methylation marks could reflect or result from biological processes occurring only with overt clinical disease or at a threshold of disease severity. This has obvious limitations for its usefulness as a diagnostic biomarker. If an epigenetic biomarker is to have greatest utility, it must be detectable in the preclinical phase and thus identified in presymptomatic individuals. Longitudinal studies that collect biological samples at baseline and follow large groups of initially healthy individuals over time to track disease incidence are thus essential.
Tissue specificity of epigenetic marks
Dementia is a disease of the brain, and a number of studies have now shown epigenetic disruption in specific brain regions in individuals diagnosed with dementia [85] . An epigenome-wide association study (HM450K) of 708 dorsolateral prefrontal cortex brain samples, for example, identified 71 sites that were differentially methylated in association with AD pathology [86] . Eleven of these sites were validated in an independent sample (n 5 117). However, there is little evidence to suggest that brain epigenetic modifications observed in AD will correlate strongly with epigenetic alterations observed in peripheral tissue. Indeed of the 12 studies included in this review, which measured DNA methylation in specific brain regions and in peripheral blood [29, 33, [40] [41] [42] 47, 50, 51, [61] [62] [63] [64] , only four studies reported methylation changes in both tissues, and this was likely to be driven by the underlying genetic repeats within C9orf72 [61] [62] [63] [64] . The majority of studies found no correlation between brain and blood methylation in dementia. For example, one study showed that SORL1 and SIRT1 methylation was not found to be significantly different between AD and controls in leukocytes or brain regions (entorhinal and auditory cortices and hippocampus) [50] ; however, there was tissue-specific increased methylation between leukocytes and brain tissue in both groups (61 AD cases: D 118.0%; 51 controls: D 113.9%). Another more recent HM450K study (n 5 41) also examined cross-tissue methylation differences and reported no strong evidence of a link between peripheral blood CD41 lymphocyte methylation profiles and AD-associated methylation differences in the dorsolateral prefrontal cortex [33] . The methylation-specific profile of different cells also contributes to the complexity of analyzing brain tissue. Hypermethylation of ANK1, for example, has been reported in the superior temporal gyrus and prefrontal cortex, but not in cerebellum (nor in peripheral blood) [41] .
Together these findings suggest that dementia-associated DNA methylation changes detected in peripheral blood are unlikely to correlate directly with the neurodegenerative process of dementia. Yet there is evidence to indicate that these blood DNA methylation marks may mediate detectable transcriptomic changes [41] , emphasizing their potential usefulness in clinical biomarker development. This is particularly the case given the difficulty in accessing brain tissue and inability to collect longitudinal brain samples to track disease diagnosis [87] .
In addition to differences across tissues, the cellspecific nature of epigenetic patterns also needs to be kept in mind when interpreting the results of studies in this area. Although all studies in this review have measured DNA methylation in blood, only one study controlled for the estimated proportion of the different cell types, and none considered measuring methylation in individual cell types following sorting of the cells. Thus, it remains possible that differences in cell composition between groups, for example, an increase in monocytes in AD individuals compared with control groups [88] , could drive some of the reported associations or mask potential differences between groups. Other peripheral tissues should also be considered in future studies. For example, buccal swabs are cheap and easy to collect and are thought to be closer in origin with brain tissue, having derived from the same primary germ cells within development [89] . No studies to date in this area, however, have examined DNA methylation of buccal tissue in AD.
Dynamic nature of DNA methylation
It has been well documented that DNA methylation is a dynamic epigenetic mechanism, especially in early development [90] , and in certain disease states, somatic cells can also undergo de novo methylation changes [91] . These dynamic methylomic changes remain stable in the long term and have been used to classify specific subtypes of disease [92] . However, it remains unclear exactly how dynamic DNA methylation changes can be over shorter periods. Most research to date has provided only a static snapshot of methylation states in mixed cell populations [93] , but there is some evidence that certain environmental exposures can elicit changes in blood methylation patterns over weeks [94] or even days [95] . Given that dementia has a long asymptomatic phase and generally slow progression rate, it is unlikely that short-term methylation differences would be observed. It is worth noting, however, that the time between collection of samples at baseline and follow-up in longitudinal studies and the time between sample collection and dementia onset or severity of disease state are potentially important considerations for future studies in this area.
Methods used to measure epigenetics
All studies included in this review measured DNA methylation, which is the most widely investigated epigenetic mechanism, with the most advanced analysis tools, thus enabling high throughput processing. This, combined with its relative cost effectiveness, makes it particularly appealing for cohort studies. However, the range of methods used to measure DNA methylation is vast [96, 97] , as are the individual laboratory processes, conditions, and methods of data analysis; including site-by-site analysis, regional methylation changes, preclustering or grouping of sites, and the identification of differentially methylated regions [98] . This large heterogeneity can make it difficult to directly compare findings, particularly with studies published more than a decade ago and because the field is expanding at such a rapid rate. There are ongoing attempts to help standardize these analysis approaches, which will be an important step in improving the relatability of findings and replication across studies [99] . The importance of internal and external validation of findings within a given study is also increasingly recognized. It is hoped this will lead to more robust research and minimize the number of chance findings (type 1 errors), which can never be replicated.
As mentioned, DNA methylation has been the predominant focus of studies not only in this area, but in the broader field to date. It is highly likely however that other epigenetic processes such as histone modifications and noncoding RNAs are also implicated in dementia and could also have potential as biomarkers [100, 101] . For example, transcriptional dysregulation has been observed in Huntington's disease where histone acetylation is involved [102] . Clinical trials have also observed that histone acetyl-transferase and histone deacetylase inhibitors have beneficial outcomes for those suffering from Huntington's disease. Further studies could also consider 5-hydroxymethylcytosine, which has been shown to modify tau-induced neurotoxicity [103] . However, their potential to also be blood biomarkers of dementia has not been established.
Comparison with other peripheral biomarkers
Current biomarkers that are used to aid in dementia diagnosis include procedures that are invasive in nature, such as PET and CSF collection. For a PET scan, the procedure is a lengthy and uncomfortable process. Patients need to fast for at least 4 hours before an injection of a radioactive compound into their blood stream and then need to wait half an hour before imaging [104] . A lumbar puncture is required for the collection of CSF and involves penetrating a patient in the lower back with a large needle, which is extremely invasive and has adverse side effects [105, 106] . Both these techniques are costly, require a specialist, and are performed in select locations. In contrast, a blood sample is relatively quick and easy to collect, with minimal side effects and much higher patient acceptability. Blood collection is already a routine part of regular medical checkups, and as such, this would greatly facilitate the implementation of general population screening if a promising biomarker was identified.
Beyond epigenetics, a number of other blood-based biomarkers are also being investigated but are beyond the scope of this review. This includes recent findings concerning apolipoprotein J and chemokine-309, which were both found to be increased in AD individuals compared with controls and those with MCI [107] .
Considerations for future studies in epigenetic biomarkers of dementia
To advance research in this area, we need robust studies with strong methodological designs. Ideally, such studies would involve prospective recruitment of a large cohort of healthy individuals reflective of the wider population, with longitudinal follow-up and sampling over several decades, including regular and in-depth collection of demographic, lifestyle, and health data (enabling later adjustment for a wide range of potential moderating and confounding factors). Clinical assessments should include a comprehensive battery of neuropsychological assessments to track cognitive decline and the early signs of dementia. Dementia should be diagnosed and adjudicated by an expert panel using the results of cognitive tests, detailed medical histories, blood tests, clinical examinations, and with structural imaging. Blood samples should be collected at recruitment (prediagnosis) and across multiple time points, not only allowing for preclinical biomarker discovery but also monitoring of changes in these biomarkers with the occurrence of disease symptoms.
In terms of epigenetics, whole epigenome-bisulfite sequencing should ideally be performed to measure DNA methylation patterns at single base-pair resolution throughout the genome. This unbiased approach of interrogating sites throughout the entire genome would undoubtedly help uncover novel sites and genes of interest. This information could then be analyzed alongside genomic data, enabling important teasing out of epigenetic-specific associations from underlying genetic risk. Unfortunately, however, these kinds of comprehensive studies may be years off, due to the technical complexity of genome and epigenome sequencing, the complex analysis and importantly the prohibitive high costs, especially for large studies which are needed here.
Currently, a more viable option would be to use the newest technology in array-based analysis, the Infinium MethylationEPIC BeadChip, which provides methylation information for over 850,000 CpG sites throughout the genome [108] . Such a large amount of comprehensive data would allow for the creation of epigenetic risk profiles, akin to the genetic risk profiles, and the potential for a preclinical diagnostic marker. The main limitation of this platform, however, is that these arrays are still quite expensive, especially when obtaining data on a large number of participants at multiple time points. The field however is progressing at an ever-increasing rate and with continual advances in epigenetic technologies, it is likely that new and improved approaches will also become available; however, the costs of these are again likely to be high [109] .
Conclusion
This review has highlighted the gaps in our understanding of peripheral DNA methylation biomarkers of dementia, with as yet insufficient evidence to draw any clear conclusions. Currently, methods of methylation analysis and outcomes are highly heterogeneous, and the populations within these studies are mostly small or very small, deriving from a limited number of populations. This is a limiting factor in current research; however, the field is still in its infancy. The oldest article included in this review was published 9 years ago, with 90% of articles published in the last 6 years. Although the findings are variable and taking into account positive publication bias, it is worth noting that a number of studies did find differential methylation in association with dementia. It is likely that genomic and epigenomic analysis of genes would provide more comprehensive answers about the real utility of DNA methylation as a biomarker of dementia. Ideally, future analyses would have robust assessments of AD and related dementias and would employ longitudinal data with individuals both before disease onset and following clinical diagnosis. This work will further the research into clinically useful biomarkers and could potentially lead not only to concise and timely diagnosis of dementia but possibly to the discovery of predictive markers associated with preclinical disease stages. High sensitivity and specificity to differentiate AD from non-AD will need to be attained for this to have any potential as a clinically meaningful tool.
Dementia is an increasingly urgent public health issue, and research and technology continues to advance in the field of epigenetics. The findings of this review are important to summarize where the field is at and a key step that must be taken before we can advance this work further.
